Milestone Pharmaceuticals has announced the appointment of former Sanofi executive Amit Hasija as Chief Financial Officer and Executive VP of Corporate Development. Milestone’s etripamil, an intranasal calcium channel antagonist, is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Hasija was most recently Chief Business Officer at Fulcrum Therapeutics. From 2012-2017, he served in several executive positions at Sanofi, including as VP, US Head of Integrated Care.
Milestone Pharmaceuticals President and CEO Joseph Oliveto commented, “It is a pleasure to welcome Amit to the Milestone team. His extensive experience across a range of financial and business development roles will be invaluable as we continue to advance our Phase 3 program of etripamil for PSVT, prepare our commercialization strategy, and begin to build out our pipeline. I look forward to working with Amit as we strive towards our goal of bringing effective therapies to patients with episodic cardiovascular conditions.”
Hasija said, “I am excited to be joining such a highly accomplished team at this important juncture for the company. I look forward to contributing to Milestone’s continued success as the etripamil development program progresses.”
Read the Milestone Pharmaceuticals press release.
